204 related articles for article (PubMed ID: 30339906)
1. Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.
Thakkar SG; Warnken ZN; Alzhrani RF; Valdes SA; Aldayel AM; Xu H; Williams RO; Cui Z
J Control Release; 2018 Dec; 292():111-118. PubMed ID: 30339906
[TBL] [Abstract][Full Text] [Related]
2. Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.
Xu H; Ruwona TB; Thakkar SG; Chen Y; Zeng M; Cui Z
Hum Vaccin Immunother; 2017 Nov; 13(11):2688-2694. PubMed ID: 28933668
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of Antigen Adjuvanted with AS04 and Its Deposition in the Upper Respiratory Tract after Intranasal Administration.
Xu H; Alzhrani RF; Warnken ZN; Thakkar SG; Zeng M; Smyth HDC; Williams RO; Cui Z
Mol Pharm; 2020 Sep; 17(9):3259-3269. PubMed ID: 32787271
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of thin-film freeze-dried, aluminum salt-adjuvanted vaccine when exposed to different temperatures.
Thakkar SG; Ruwona TB; Williams RO; Cui Z
Hum Vaccin Immunother; 2017 Apr; 13(4):936-946. PubMed ID: 28051903
[TBL] [Abstract][Full Text] [Related]
5. A method of lyophilizing vaccines containing aluminum salts into a dry powder without causing particle aggregation or decreasing the immunogenicity following reconstitution.
Li X; Thakkar SG; Ruwona TB; Williams RO; Cui Z
J Control Release; 2015 Apr; 204():38-50. PubMed ID: 25735896
[TBL] [Abstract][Full Text] [Related]
6. Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01).
Hellfritzsch M; Christensen D; Foged C; Scherließ R; Thakur A
Int J Pharm; 2023 Dec; 648():123581. PubMed ID: 37931728
[TBL] [Abstract][Full Text] [Related]
7. Curdlan sulfate-
Zhang S; Huang S; Lu L; Song X; Li P; Wang F
Int J Nanomedicine; 2018; 13():2377-2394. PubMed ID: 29713168
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders.
Yu YS; AboulFotouh K; Xu H; Williams G; Suman J; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z
Int J Pharm; 2023 Jun; 640():122990. PubMed ID: 37127138
[TBL] [Abstract][Full Text] [Related]
9. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of monophosphoryl lipid A as adjuvant for pulmonary delivered influenza vaccine.
Patil HP; Murugappan S; ter Veer W; Meijerhof T; de Haan A; Frijlink HW; Wilschut J; Hinrichs WL; Huckriede A
J Control Release; 2014 Jan; 174():51-62. PubMed ID: 24269505
[TBL] [Abstract][Full Text] [Related]
11. Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.
Velasquez LS; Shira S; Berta AN; Kilbourne J; Medi BM; Tizard I; Ni Y; Arntzen CJ; Herbst-Kralovetz MM
Vaccine; 2011 Jul; 29(32):5221-31. PubMed ID: 21640778
[TBL] [Abstract][Full Text] [Related]
12. Thin-Film Freeze-Drying Is a Viable Method to Convert Vaccines Containing Aluminum Salts from Liquid to Dry Powder.
Alzhrani RF; Xu H; Moon C; Suggs LJ; Williams RO; Cui Z
Methods Mol Biol; 2021; 2183():489-498. PubMed ID: 32959262
[TBL] [Abstract][Full Text] [Related]
13. First in vivo evaluation of particulate nasal dry powder vaccine formulations containing ovalbumin in mice.
Scherließ R; Mönckedieck M; Young K; Trows S; Buske S; Hook S
Int J Pharm; 2015 Feb; 479(2):408-15. PubMed ID: 25595389
[TBL] [Abstract][Full Text] [Related]
14. Stable dry powder formulation for nasal delivery of anthrax vaccine.
Wang SH; Kirwan SM; Abraham SN; Staats HF; Hickey AJ
J Pharm Sci; 2012 Jan; 101(1):31-47. PubMed ID: 21905034
[TBL] [Abstract][Full Text] [Related]
15. Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co-adsorption of ALF or ALFQ adjuvant to the aluminum-antigen complex.
Beck Z; Torres OB; Matyas GR; Lanar DE; Alving CR
J Control Release; 2018 Apr; 275():12-19. PubMed ID: 29432824
[TBL] [Abstract][Full Text] [Related]
16. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats.
Huang J; Garmise RJ; Crowder TM; Mar K; Hwang CR; Hickey AJ; Mikszta JA; Sullivan VJ
Vaccine; 2004 Dec; 23(6):794-801. PubMed ID: 15542204
[TBL] [Abstract][Full Text] [Related]
17. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
18. Cell-penetrating peptide-linked polymers as carriers for mucosal vaccine delivery.
Sakuma S; Suita M; Inoue S; Marui Y; Nishida K; Masaoka Y; Kataoka M; Yamashita S; Nakajima N; Shinkai N; Yamauchi H; Hiwatari K; Tachikawa H; Kimura R; Uto T; Baba M
Mol Pharm; 2012 Oct; 9(10):2933-41. PubMed ID: 22953762
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production.
Iyer S; HogenEsch H; Hem SL
Vaccine; 2003 Mar; 21(11-12):1219-23. PubMed ID: 12559801
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.
Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A
PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
